Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Phase 1 Completed
100 enrolled
Study of DF6215 in Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Pilot Study of Radiation-Induced Xerostomia Treatment With Allogeneic Mesenchymal Stromal Stem Cells
Phase 1 Completed
10 enrolled
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Phase 1 Completed
10 enrolled
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
Phase 1 Completed
67 enrolled
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
Phase 1 Completed
21 enrolled
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1 Completed
80 enrolled
Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma
Phase 1 Completed
9 enrolled
Pembrolizumab in Combination With CRT for LA-SCCHN
Phase 1 Completed
59 enrolled 9 charts
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
Phase 1 Completed
13 enrolled 12 charts
CLR 131 Combined With Radiation for Head and Neck Cancer
Phase 1 Completed
12 enrolled 27 charts
GX-051
Phase 1 Completed
12 enrolled
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
Phase 1 Completed
146 enrolled 38 charts
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Completed
260 enrolled 52 charts
DEHART
Phase 1 Completed
18 enrolled 12 charts
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Phase 1 Completed
272 enrolled
A Study of CDX-585 in Patients With Advanced Malignancies
Phase 1 Completed
20 enrolled
Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
Phase 1 Completed
24 enrolled
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
Phase 1 Completed
13 enrolled
EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients
Phase 1 Completed
39 enrolled
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
Phase 1 Completed
54 enrolled
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
Phase 1 Completed
39 enrolled
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Phase 1 Completed
58 enrolled
Anti-platelet + Pembro for H&N Tumors
Phase 1 Completed
20 enrolled
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Completed
139 enrolled 36 charts
A First in Human, Dose Escalation Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors
Phase 1 Completed
38 enrolled
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Phase 1 Completed
12 enrolled
DUET-3
Phase 1 Completed
198 enrolled
Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.
Phase 1 Completed
60 enrolled
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
Phase 1 Completed
29 enrolled
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Phase 1 Completed
132 enrolled
A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
Phase 1 Completed
47 enrolled
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers
Phase 1 Completed
45 enrolled
Anti-OX40 Antibody in Head and Neck Cancer Patients
Phase 1 Completed
17 enrolled
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Phase 1 Completed
43 enrolled
Radiotherapy of Tongue Cancer Using an Intraoral Stent
Phase 1 Completed
13 enrolled
Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
Phase 1 Completed
31 enrolled
Resistance Training and Physical Functioning in Head and Neck Cancer Patients
Phase 1 Completed
18 enrolled
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Phase 1 Completed
71 enrolled
Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Phase 1 Completed
19 enrolled
Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
Phase 1 Completed
230 enrolled
Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer
Phase 1 Completed
50 enrolled
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Phase 1 Completed
27 enrolled
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Phase 1 Completed
14 enrolled 12 charts
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Phase 1 Completed
37 enrolled
A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia
Phase 1 Completed
24 enrolled
A Study of PRT1419 in Patients With Advanced Solid Tumors
Phase 1 Completed
26 enrolled
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
Phase 1 Completed
193 enrolled
Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
Phase 1 Completed
20 enrolled
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Phase 1 Completed
15 enrolled